Skip to content
Shagandha®
  • About Shagandha®
    • Introduction
    • Traditional Significance
    • Chemistry
    • Why Shagandha®?
      • Complies with USP monograph
      • NON-GMO Project Verified
    • Benefits
  • Research
    • Preclinical
    • Clinical
    • Publications
  • IP Rights
    • Patents
    • Trademark Licence
  • About Sabinsa
    • Newsroom
      • Press Releases
      • Shagandha® Book
      • Ads
      • FAQs
  • Contact Us

Sami-Sabinsa Group Acquires Exclusive Global Marketing Rights for European and USA Patents on Oroxylum indicium

The Sami-Sabinsa Group, which manufactures and markets phytonutrients and standardized herbal extracts, specialty fine chemicals, and organic intermediates used in the nutritional, cosmeceutical and food industries worldwide, has acquired exclusive global marketing rights for two patents on Oroxylum indicum from one of India’s longest-established R&D labs, the Indian Institute of Chemical Technology (CSIR), Hyderabad. The specific patents are European EP1986670 and USA US7855200.

Both patents disclose the biological use of bioactive compounds isolated from the plant Oroxylum indicum. US7855200 discloses a method of treating gastric ulcers induced by aspirin using a composition containing Oroxylin A, Baicalein and Chrysin isolated from Oroxylum indicum. Patent EP1986670 discloses the use of bioactive molecules Oroxylin A, Baicalein and Chrysin as a potent alpha-glucosidase inhibitor, used as a supplement or incorporated into pharmaceuticals, food products and health foods for treating hyperglycemia (elevated glucose levels). These bioactives have great potential in alleviating the symptoms of hyperglycemia associated with diabetes, obesity and other related conditions. The licensed invention relates to methods of using Oroxylum indicum as a rich source for flavonoid compounds having mucoprotective and antigastric ulcer properties, and containing Oroxylin A, Chrysin and Baicalein.

Dr. Muhammed Majeed, Founder & Chairman of the Sami-Sabinsa Group signed the agreement with Dr. D. Shailaja, Head of Business Development and Research Management & Senior Principal Scientist, CSIR – Indian Institute of Chemical Technology at Sami Labs Bangalore, India office. “This accomplishment is another important milestone as it accelerates our mission to provide quality products that benefit human health throughout the world,” said Dr. Majeed. “With our global presence, we will be able to bring this ancient remedy supported by modern research into the marketplace.”

Oroxylum indicum is a species of flowering plant belonging to the monotypic genus Oroxylum and the family Bignoniaceae, customarily called a variety of intriguing names including midnight horror, Indian trumpet flower, broken bones, Indian caper, and tree of Damocles. Traditional Ayurvedic medicinal uses of Oroxylum indicum include: the decoction of the bark from the plant taken for curing gastric ulcer; a paste made of the bark powder applied for mouth cancer, scabies, and other skin diseases; the seed is ground with fire-soot into a paste applied to the neck for quick relief of tonsil pain; a paste made of the bark applied to the wounds of animals to kill maggots; and a decoction of the bark is given to animals for de-worming. The plant is also claimed to have anti-cancer properties.

Back

About Sabinsa

Sabinsa is a manufacturer, supplier and marketer of herbal extracts, cosmeceuticals, minerals, dietary supplements and specialty fine chemicals for the nutritional, cosmetic, pharmaceutical and food industries.

Read More..

Headquarters

Sabinsa Corporation

20 Lake Drive 

East Windsor

NJ 08520, USA

 

Tel : +1 732 777 1111

Fax: +1 732 777 1443

info@sabinsa.com

Global Contact List

USAIndia
Utah, USAJapan
AustraliaPoland
BrasilKorea
CanadaSouth Africa
ChinaVietnam
Germany 

Contact us

    © 2025 Sabinsa. All Rights Reserved | Privacy Policy | Sitemap | Terms of Use | Disclaimer

    ×

    Disclaimer

    US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

    EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.